Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N, De Palo G, Formelli F, Costa A, Marubini E, Campa T, Crippa A, Danesini GM, Delle Grottaglie M, Di Mauro MG, et al. Rotmensz N, et al. Among authors: de palo g. Eur J Cancer. 1991;27(9):1127-31. doi: 10.1016/0277-5379(91)90309-2. Eur J Cancer. 1991. PMID: 1835622 Clinical Trial.
Chemoprevention of breast cancer.
De Palo G, Costa A, Formelli F, Del Vecchio M, Marubini E, Veronesi U. De Palo G, et al. In Vivo. 1993 Nov-Dec;7(6B):577-80. In Vivo. 1993. PMID: 8193278 Review.
Fenretinide (4-HPR) in chemoprevention of oral leukoplakia.
Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, Mariani L, Formelli F, Giardini R, Costa A, De Palo G, et al. Chiesa F, et al. Among authors: de palo g. J Cell Biochem Suppl. 1993;17F:255-61. doi: 10.1002/jcb.240531038. J Cell Biochem Suppl. 1993. PMID: 8412202 Clinical Trial.
Chemoprevention of breast cancer with fenretinide.
Veronesi U, De Palo G, Costa A, Formelli F, Decensi A. Veronesi U, et al. Among authors: de palo g. IARC Sci Publ. 1996;(136):87-94. IARC Sci Publ. 1996. PMID: 8791119 Review. No abstract available.
Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
De Palo G, Camerini T, Marubini E, Costa A, Formelli F, Del Vecchio M, Mariani L, Miceli R, Mascotti G, Magni A, Campa T, Di Mauro MG, Attili A, Maltoni C, Del Turco MR, Decensi A, D'Aiuto G, Veronesi U. De Palo G, et al. Tumori. 1997 Nov-Dec;83(6):884-94. doi: 10.1177/030089169708300603. Tumori. 1997. PMID: 9526578 Clinical Trial.
178 results